Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: A Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study - 09/08/11
, Sabina A. Murphy, MPH a, Yuri B. Pride, MD c, Ajay J. Kirtane, MD, SM b, Julian M. Aroesty, MD b, Erica B. Stein, BA a, Lauren N. Ciaglo, BA a, Matthew C. Southard, BS a, Marc S. Sabatine, MD, MPH a, d, Christopher P. Cannon, MD a, d, Eugene Braunwald, MD a, dfor the TIMI Study Group
Résumé |
Background |
The use of routine nonemergent percutaneous coronary intervention (PCI) among patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolytic therapy is unknown. We sought to evaluate the effect of nonemergent PCI on mortality among patients with STEMI treated with fibrinolytic administration and the consequence of clopidogrel pretreatment on this effect.
Methods |
CLARITY-TIMI 28 randomized 3491 patients with STEMI treated with fibrinolytic administration and aspirin to clopidogrel or placebo. All patients were to undergo angiography 48 to 192 hours after randomization. Percutaneous coronary intervention was performed at the discretion of the treating physician. Nonemergent PCI, which was defined as PCI that was not precipitated by recurrent myocardial infarction, was performed in 1781 patients (55.7%).
Results |
Nonemergent PCI did not affect 30-day mortality (2.0% vs 2.3% among patients who did not undergo PCI). However, nonemergent PCI was associated with lower mortality among patients randomized to clopidogrel (1.3% vs 2.8%, P = .04) but not among those randomized to placebo (2.6% vs 1.7%, P = .25; interaction P = .025). In multivariate modeling, PCI remained associated with lower mortality among patients randomized to clopidogrel (OR 0.34, 95% CI 0.13-0.92, P = .034) but not placebo (OR 1.41, 95% CI 0.63-3.19, P = .40, interaction P = .028).
Conclusion |
Among patients with STEMI treated with fibrinolytic administration and aspirin, nonemergent PCI was associated with lower mortality among patients pretreated with clopidogrel. These results suggest that routine nonemergent PCI is beneficial among such patients, although further confirmatory randomized studies are needed.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported in part by a grant from Sanofi-Aventis, Paris, France, and Bristol-Myers Squibb, Princeton, NJ. |
Vol 155 - N° 1
P. null - janvier 2008 Retour au numéro
Article précédent
- Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow-up
- Melissa Co, Edgar Tay, Chi Hang Lee, Kian Keong Poh, Adrian Low, Jimmy Lim, Ing Han Lim, Yean Teng Lim, Huay Cheem Tan
- Culprit-only or multivessel revascularization in patients with acute coronary syndromes : An American College of Cardiology National Cardiovascular Database Registry report
- Sorin J. Brener, Sarah Milford-Beland, Matthew T. Roe, Deepak L. Bhatt, William S. Weintraub, Ralph G. Brindis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?